Literature DB >> 11477199

Pathogenesis of Shiga toxin-associated hemolytic uremic syndrome.

F Proulx1, E G Seidman, D Karpman.   

Abstract

The aim of this review is to examine recent advances in experimental and clinical research relevant to the pathogenesis of diarrhea-associated hemolytic uremic syndrome with special reference to histopathologic findings, virulence factors of Shiga toxin-producing Escherichia coli, the host response, and the prothrombotic state. Despite significant advances during the past decade, the exact mechanism by which Shiga toxin-producing E. coli leads to hemolytic uremic syndrome remains unclear. Factors such as Shiga toxin, lipopolysaccharide, the adhesins intimin and E. coli-secreted proteins A, B, and D, the 60-MD plasmid, and enterohemolysin likely contribute to the pathogenesis. Data on the inflammatory response of the host, including leukocytes and inflammatory mediators, are updated. The pathogenesis of the prothrombotic state leading to thrombocytopenia secondary to endothelial cell damage and platelet activation is also discussed. A hypothetical sequence of events from ingestion of the bacteria to the development of full-blown hemolytic uremic syndrome is proposed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11477199     DOI: 10.1203/00006450-200108000-00002

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  76 in total

1.  Shiga toxin is transported from the endoplasmic reticulum following interaction with the luminal chaperone HEDJ/ERdj3.

Authors:  Min Yu; David B Haslam
Journal:  Infect Immun       Date:  2005-04       Impact factor: 3.441

2.  Shiga toxin facilitates its retrograde transport by modifying microtubule dynamics.

Authors:  Heidi Hehnly; David Sheff; Mark Stamnes
Journal:  Mol Biol Cell       Date:  2006-08-02       Impact factor: 4.138

3.  Shiga-toxigenic Escherichia coli-inoculated neonatal piglets develop kidney lesions that are comparable to those in humans with hemolytic-uremic syndrome.

Authors:  J F Pohlenz; K R Winter; E A Dean-Nystrom
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

4.  Chemokine expression in the monocytic cell line THP-1 in response to purified shiga toxin 1 and/or lipopolysaccharides.

Authors:  Lisa M Harrison; Christel van den Hoogen; Wilhelmina C E van Haaften; Vernon L Tesh
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

5.  Retrograde Shiga toxin trafficking is regulated by ARHGAP21 and Cdc42.

Authors:  Heidi Hehnly; Katrina Marie Longhini; Ji-Long Chen; Mark Stamnes
Journal:  Mol Biol Cell       Date:  2009-08-19       Impact factor: 4.138

Review 6.  Shiga toxins--from cell biology to biomedical applications.

Authors:  Ludger Johannes; Winfried Römer
Journal:  Nat Rev Microbiol       Date:  2009-12-21       Impact factor: 60.633

7.  Shiga toxin 1-induced inflammatory response in lipopolysaccharide-sensitized astrocytes is mediated by endogenous tumor necrosis factor alpha.

Authors:  Verónica I Landoni; Marcelo de Campos-Nebel; Pablo Schierloh; Cecilia Calatayud; Gabriela C Fernandez; M Victoria Ramos; Bárbara Rearte; Marina S Palermo; Martín A Isturiz
Journal:  Infect Immun       Date:  2009-12-14       Impact factor: 3.441

8.  The MAP kinase-activated protein kinase 2 (MK2) contributes to the Shiga toxin-induced inflammatory response.

Authors:  Jose B Saenz; Jinmei Li; David B Haslam
Journal:  Cell Microbiol       Date:  2009-11-27       Impact factor: 3.715

9.  Mannan-binding lectin in children with Escherichia coli O157:H7 haemmorrhagic colitis and haemolytic uraemic syndrome.

Authors:  F Proulx; E Wagner; B Toledano; H Decaluwe; E G Seidman; G-E Rivard
Journal:  Clin Exp Immunol       Date:  2003-09       Impact factor: 4.330

10.  Epigallocatechin-3-gallate suppresses galactose-alpha1,4-galactose-1beta,4-glucose ceramide expression in TNF-alpha stimulated human intestinal epithelial cells through inhibition of MAPKs and NF-kappaB.

Authors:  Dong-Oh Moon; Se-Rim Choi; Chang-Min Lee; Gi-Young Kim; Hee-Jeong Lee; Yeong-Min Park
Journal:  J Korean Med Sci       Date:  2005-08       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.